Equasens (EQS) AI Stock Analysis

Equasens

(Paris:EQS)

Select Model

Rating:71Outperform

Price Target:EUR 30.00▲(12.15% Upside)

Action:reiterated

Date:10/31/26

The score is driven primarily by strong financial performance (durable profitability, healthy ROE, and a resilient balance sheet) and attractive valuation (low P/E and high dividend yield). These positives are partially offset by weak technicals, with price below key moving averages and negative MACD indicating bearish momentum.

Positive Factors

Durable profitabilityEquasens maintains strong profitability, with net margins generally in the high-teens to low-20s and operating margin near 20% in 2025. This indicates an established software and services model capable of producing meaningful earnings while supporting reinvestment and shareholder returns.

Negative Factors

Margin compressionAlthough profitability remains solid, the decline in margins from the stronger 2021–2023 period indicates that earnings are not expanding as efficiently as before. Continued compression could reduce operating leverage, limit reinvestment capacity, and make future profit growth more dependent on revenue expansion.

Equasens (EQS) vs. iShares MSCI France ETF (EWQ)

Market Cap: EUR 402.92M
Dividend Yield: 5.23%
Average Volume (3M): 24.04K
Price to Earnings (P/E): 9.9
Beta (1Y): 0.38
Revenue Growth: 9.04%
EPS Growth: 13.05%
Country: France
Employees: 1,462
Sector: General
Sector Strength: 55
Industry: Software - Application

Equasens Business Overview & Revenue Model

Company Description

Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their netwo...

Equasens Financial Statement Overview

Summary

Overall fundamentals are strong, supported by solid profitability (net margin generally high-teens/low-20s; operating margin ~20% in 2025), healthy ROE (~14.9% in 2025), and improving leverage with expanding equity. The score is tempered by a softer growth/margin trend versus 2021–2023, declining free cash flow growth despite strong absolute FCF (~47.1M in 2025), and some reported data gaps/inconsistencies that reduce visibility (e.g., missing/zero gross profit and cash-conversion metrics in 2025).

Income Statement

78Positive

Balance Sheet

80Positive

Cash Flow

73Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	245.05M	236.52M	216.75M	219.79M	214.07M	193.07M
Gross Profit	52.53M	49.74M	47.13M	56.66M	59.01M	53.81M
EBITDA	69.16M	65.30M	59.44M	68.63M	68.53M	62.18M
Net Income	41.04M	39.33M	36.23M	47.05M	46.25M	39.12M
Balance Sheet
Total Assets	450.80M	439.00M	398.01M	394.05M	350.81M	329.95M
Cash, Cash Equivalents and Short-Term Investments	69.00M	87.10M	40.16M	54.69M	68.01M	64.79M
Total Debt	57.08M	53.80M	48.45M	69.27M	66.52M	84.06M
Total Liabilities	190.00M	176.00M	157.32M	166.42M	154.01M	164.72M
Stockholders Equity	249.95M	252.28M	231.51M	219.28M	189.78M	159.00M
Cash Flow
Free Cash Flow	29.24M	47.10M	35.91M	43.17M	46.75M	37.09M
Operating Cash Flow	31.67M	59.20M	47.55M	61.59M	56.98M	47.52M
Investing Cash Flow	-34.51M	-12.10M	-13.90M	-50.53M	-20.82M	-36.19M
Financing Cash Flow	3.98M	-48.50M	-36.20M	-16.09M	-39.88M	-9.80M

Equasens Technical Analysis

Technical Analysis SentimentNegative

Last Price26.75

Price Trends

50DMA30.49Negative

100DMA32.16Negative

200DMA34.16Negative

Market Momentum

MACD-0.44Negative

RSI31.29Neutral

STOCH61.76Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Negative. The current price of 26.75 is below the 20-day moving average (MA) of 28.90, below the 50-day MA of 30.49, and below the 200-day MA of 34.16, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 31.29 is Neutral, neither overbought nor oversold. The STOCH value of 61.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EQS.

Equasens Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

FR:EQS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:EQS	71Outperform	EUR 401.80M	9.91	16.34%	5.23%	9.04%	13.05%
FR:ALCGM	60Neutral	EUR 133.03M	-9.06	-5.44%	―	-0.98%	―
FR:ALERS	58Neutral	EUR 258.39M	37.57	3.89%	―	6.28%	204.56%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
FR:ALMDT	43Neutral	EUR 180.85M	-3.00	271.64%	―	2.16%	-5.26%

* General Sector Average

Performance Comparison

FR:EQS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FR:EQS	Equasens Société	26.75	-9.23	-25.65%
FR:ALCGM	Cegedim SA	9.70	-2.05	-17.45%
FR:ALERS	Eurobio-Scientific SA	26.30	2.15	8.90%
FR:ALMDT	Median Technologies	3.69	0.79	27.24%
FR:ALBIO	Biosynex SA	0.84	0.23	37.05%
FR:ABLD	ABL Diagnostics SA	2.28	-1.59	-41.10%

Equasens Corporate Events

Equasens Posts Solid Nine-Month Revenue Growth on Software and Services Strength

Oct 29, 2026

Equasens reported revenue of €181.8m for the first nine months of 2026, up 5.6% on a reported basis and 0.9% organically, driven by solid growth in its PHARMAGEST and AXIGATE LINK divisions and a strong rise in maintenance, subscription and sof...

Equasens Files 2026 Half-Year Financial Report with AMF

Sep 29, 2026

Equasens announced that it has filed its 2026 half-year financial report with the French market regulator, the Autorité des Marchés Financiers, on 29 September 2026. The report, which includes the half-year activity review, consolidated fin...

Equasens Delivers Higher H1 2026 Revenue and Margins on Acquisitions and Recurring Sales

Sep 28, 2026

Equasens reported first-half 2026 revenue of €124.5m, up 7.3%, driven mainly by the acquisition of Erevo and the integration of Novaprove and DIS, while like-for-like growth remained modest at 1.4%. Annual recurring revenue rose 8.8% to €...

Equasens Activates Business Continuity Plan After Fire at ASCA Site

Sep 22, 2026

Equasens has activated its business continuity plan after a fire destroyed the head office and storage site of its pharmacy electronic labelling subsidiary ASCA in Chessy, where 25 employees work and stocks for installations were held. Although the b...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Equasens AI Stock Analysis